Eli Lilly and Company
(LLY : NYQ)
Sector: Healthcare | Industry: Drug Manufacturers - General
$1,283.66
+43.32 (+3.49%)
MARKET CAP
$1.14T
FCF YIELD
0.97%
CURRENT PRICE
$1,283.66
P/E RATIO
41.64x
MODEL INPUTS
Intrinsic Fair Value
$454.16
per share
5-YEAR FREE CASH FLOW PROJECTIONS
| Year | Projected FCF | Discount Factor (WACC) | Present Value (PV) |
|---|---|---|---|
| Base (0) | $11.07B | - | - |
| Year 1 | $13.97B | at 26.2% growth | $12.81B |
| Year 2 | $17.62B | at 26.2% growth | $14.83B |
| Year 3 | $22.24B | at 26.2% growth | $17.17B |
| Year 4 | $28.07B | at 26.2% growth | $19.88B |
| Year 5 | $35.42B | at 26.2% growth | $23.02B |
VALUATION ARITHMETIC
| Valuation Step | Value |
|---|---|
| PV of Projected FCFs (Sum Y1-Y5) | $87.73B |
| Terminal Value (Perpetuity at 2.5%) | $558.59B |
| PV of Terminal Value | $363.05B |
| Enterprise Value (EV) | $450.77B |
| Less: Total Debt | -$54.91B |
| Add: Total Cash & Equivalents | +$8.95B |
| Equity Value | $404.82B |
| Divided by: Shares Outstanding | 891,357,065.00 |
| Intrinsic Value (Fair Value per Share) | $454.16 |
FINANCIAL RATIOS & STATS
| Financial Metric | Value |
|---|---|
| Trailing P/E | 41.64x |
| Forward P/E | 27.19x |
| Price-to-Book (P/B) | 33.78x |
| Price-to-Sales (P/S) | 14.36x |
| Net Profit Margin (Net Income / Revenue) | 33.53% |
| Operating Profit Margin (EBIT / Revenue) | 54.22% |
| Return on Equity (ROE) | 102.29% |
| Return on Assets (ROA) | 20.36% |
| Dividend Rate | $6.92 |
| Dividend Yield | 0.54% |
| Ex-Dividend Date | 2026-08-14 |
| Next Earnings Date | 2026-10-29 |